Sophie P. V.
- Country
- France
- Department
- Oncology
Research Overview
- Phase 1a/b Study of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced Solid Tumors with MTAP Deletion or Loss of MTAP Expression
- Phase I/IIa Study of AZD3470 Monotherapy and Combination Therapy in MTAP-Deficient Advanced Solid Tumors
- Phase 1/2 Study of DF6002 Monotherapy and DF6002 with Nivolumab in Patients with Advanced Solid Tumors
Data & Insights
Has run more than one trial at 18 of 46 partner sites.
Specializations
Myeloid Hematologic Malignancies
The investigator concentrates on aggressive myeloid diseases, emphasizing therapeutic strategies for patients with limited treatment options.
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- AML with IDH1/2 mutations
- Relapsed or refractory AML
Research integrates targeted agents and transplant approaches to improve remission durability.
Targeted Solid Tumor Oncology
Focus is placed on solid cancers driven by specific genomic alterations, guiding precision‑medicine interventions.
- MTAP‑deleted tumors
- KRAS G12C‑mutated cancers
- HER2‑positive or HER2‑low malignancies
- ALK‑rearranged non‑small cell lung cancer
- RET‑fusion positive cancers
Therapeutic development targets these molecular drivers across lung, colorectal, pancreatic, and biliary tract sites.
Immuno‑Oncology and Checkpoint Modulation
Clinical programs explore immune‑based regimens to enhance antitumor immunity in advanced disease settings.
- PD‑1/PD‑L1 checkpoint inhibition
- Tumor Mutational Burden‑high cancers
- Microsatellite Instability‑high (MSI‑H) tumors
- Mismatch Repair‑deficient malignancies
- Immune‑checkpoint refractory melanoma
Efforts include combination strategies and biomarker‑guided patient selection.
Allogeneic Stem Cell Transplantation & GVHD
The investigator participates in transplant programs aimed at curative intent for high‑risk hematologic cancers while addressing post‑transplant immune complications.
- Allogeneic hematopoietic stem cell transplantation
- Acute graft‑versus‑host disease
- Chronic graft‑versus‑host disease
- HLA‑matched donor selection
- Reduced‑intensity conditioning regimens
Research seeks to optimize engraftment, minimize toxicity, and improve long‑term survival.
Rare and Aggressive Tumor Subtypes
Specialized studies target malignancies with limited therapeutic options, including high‑grade sarcomas and neuroendocrine neoplasms.
- Malignant mesothelioma
- High‑grade sarcoma
- Neuroendocrine tumors of the lung and gastrointestinal tract
- Glioblastoma multiforme
- Merkel cell carcinoma
Innovative therapeutic avenues are evaluated to address these challenging disease entities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.